Form 4 for PCSA Processa Pharmaceuticals, Inc.

Accepted 2024-02-01 00:00:00 ET · period of report 2024-01-31 · accession 0000897069-24-000236 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2024-02-01	2024-01-31+	PCSA	Lin Patrick	Chief Business - Strategy Off	P - Purchase	$2.38	+4,000	27.5K	+17%	+$9,525

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-01-31	P	A	2,500	$2.37	25,978	D	—	—	(F1) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
2	Common	Common Stock	2024-02-01	P	A	1,500	$2.40	27,478	D	—	—	(F1) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.